Home › Companies › NewAmsterdam Pharma Company N.V. › 2025-2026
Compiled from SEC Form N-PX filings and NewAmsterdam Pharma Company N.V.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 2, 2026: 10 items on NewAmsterdam Pharma Company N.V.’s Form 8-K, filed June 3, 2026: 8 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore NewAmsterdam Pharma Company N.V. in the interactive database Compare manager voting policies
These tallies are NewAmsterdam Pharma Company N.V.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025 | 91,484,326 | 3,855 | 50,431 | -- | -- | 99.9% | Approved | — |
| 2. The discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2025 | 85,229,605 | 1,105,840 | 51,557 | -- | 5,151,610 | 99% | Approved | — |
| 3. The instruction to Deloitte Accounts B.V. as the external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year | 91,502,529 | 4,636 | 31,447 | -- | -- | 99.9% | Approved | — |
| 4. The selection by the Company's Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 | 91,502,639 | 4,618 | 31,355 | -- | -- | 99.9% | Approved | — |
| Elect Director: John W. Smither | 85,375,639 | 956,620 | 54,743 | -- | 5,151,610 | 99% | Not verified | — |
| Elect Director: Janneke van der Kamp | 75,256,863 | 9,899,189 | 1,230,950 | -- | 5,151,610 | 88% | Not verified | — |
| 6. The extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company's capital, for a five-year period ending June 2, 2031 | 59,539,558 | 26,801,646 | 45,798 | -- | 5,151,610 | 69% | Approved | — |
| 7. The extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031 | 57,890,766 | 28,450,917 | 45,319 | -- | 5,151,610 | 67% | Approved | — |
| 8. The ESPP | 86,221,442 | 139,927 | 25,633 | -- | 5,151,610 | 99.8% | Approved | — |
| 9. The 2025 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote | 81,100,259 | 4,946,963 | 339,780 | -- | 5,151,610 | 94% | Approved | — |
Source: NewAmsterdam Pharma Company N.V., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.
Each item below shows how the 185 asset managers that disclosed a NewAmsterdam Pharma Company N.V. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NewAmsterdam Pharma Company N.V.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Reappointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Janneke van der Kamp until the 2030 annual general meeting
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: Janneke van der Kamp”): 75,256,863 for, 9,899,189 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 21,450,616 for, 2,472,463 against, 1,010,862 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 982,142 | 0 | Abstain |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 474,913 | 0 | 0 | Against |
| American Century | 0 | 419,067 | 0 | 0 | Against |
| AllianceBernstein | 0 | 404,858 | 0 | 0 | Against |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 291,102 | 0 | 0 | Against |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 727 | 172,663 | 0 | 0 | Against |
| Equitable | 31,710 | 112,138 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 0 | 132,778 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 96,492 | 0 | 0 | Against |
| Principal | 0 | 87,095 | 0 | 0 | Against |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 0 | 78,965 | 0 | 0 | Against |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Reappointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: John W. Smither until the 2030 annual general meeting
NewAmsterdam Pharma Company N.V.’s own tally for this item (“Elect Director: John W. Smither”): 85,375,639 for, 956,620 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 24,905,221 for, 28,720 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 2 wordings of this item as funds reported it.
69% Approved · of votes cast
Description as filed by funds: EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO ISSUE ORDINARY SHARES (OR RIGHTS TO SUBSCRIBE FOR ORDINARY SHARES) IN THE COMPANY'S CAPITAL.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“6. The extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company's capital, for a five-year period ending June 2, 2031”): 59,539,558 for, 26,801,646 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the extension of authorization for the Board of Directors to issue Ordinary Shares (or rights to subscribe for Ordinary Shares) in the Company's capital, for a five-year period ending June 2, 2031.”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 8,359,340 for, 16,574,601 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 1,638,968 | 7,692,745 | 0 | 0 | Mixed |
| Fidelity | 5,187,037 | 29,422 | 0 | 0 | For |
| Vanguard | 134,879 | 3,065,763 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 982,142 | 0 | 0 | Against |
| NEW ECONOMY FUND | 0 | 957,477 | 0 | 0 | Against |
| Prudential/PGIM | 611,111 | 64,490 | 0 | 0 | Mixed |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 474,913 | 0 | 0 | Against |
| American Century | 0 | 419,067 | 0 | 0 | Against |
| AllianceBernstein | 0 | 404,858 | 0 | 0 | Against |
| BlackRock | 0 | 340,338 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 291,102 | 0 | 0 | Against |
| Federated Hermes | 0 | 238,053 | 0 | 0 | Against |
| BNY Mellon | 0 | 176,721 | 0 | 0 | Against |
| Victory Capital | 0 | 173,390 | 0 | 0 | Against |
| Equitable | 13,851 | 129,997 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 0 | 132,778 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 96,492 | 0 | 0 | Against |
| Principal | 0 | 87,095 | 0 | 0 | Against |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 81,840 | 0 | 0 | Against |
| Eaton Vance | 0 | 81,652 | 0 | 0 | Against |
| Allspring | 0 | 78,965 | 0 | 0 | Against |
| Brighthouse | 0 | 62,244 | 0 | 0 | Against |
| OPTIMUM FUND TRUST | 0 | 60,861 | 0 | 0 | Against |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
67% Approved · of votes cast
Description as filed by funds: EXTENSION OF AUTHORIZATION FOR THE BOARD OF DIRECTORS TO LIMIT OR EXCLUDE PRE-EMPTION RIGHTS.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“7. The extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031”): 57,890,766 for, 28,450,917 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the extension of authorization for the Board of Directors to limit or exclude pre-emption rights, for a five-year period ending June 2, 2031.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 7,666,201 for, 17,235,519 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 1,638,968 | 7,692,745 | 0 | 0 | Mixed |
| Fidelity | 5,185,849 | 30,610 | 0 | 0 | For |
| Vanguard | 134,879 | 3,065,763 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 982,142 | 0 | 0 | Against |
| NEW ECONOMY FUND | 0 | 957,477 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 675,601 | 0 | 0 | Against |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 474,913 | 0 | 0 | Against |
| American Century | 0 | 419,067 | 0 | 0 | Against |
| AllianceBernstein | 0 | 404,858 | 0 | 0 | Against |
| BlackRock | 0 | 340,338 | 0 | 0 | Against |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 291,102 | 0 | 0 | Against |
| Federated Hermes | 0 | 238,053 | 0 | 0 | Against |
| BNY Mellon | 0 | 176,721 | 0 | 0 | Against |
| Victory Capital | 0 | 173,390 | 0 | 0 | Against |
| Equitable | 13,851 | 129,997 | 0 | 0 | Mixed |
| FRANKLIN STRATEGIC SERIES | 0 | 132,778 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 96,492 | 0 | 0 | Against |
| Principal | 0 | 87,095 | 0 | 0 | Against |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 81,840 | 0 | 0 | Against |
| Eaton Vance | 0 | 81,652 | 0 | 0 | Against |
| Allspring | 0 | 78,965 | 0 | 0 | Against |
| Brighthouse | 0 | 62,244 | 0 | 0 | Against |
| OPTIMUM FUND TRUST | 0 | 60,861 | 0 | 0 | Against |
Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: DISCHARGE FROM LIABILITY FOR THE COMPANY'S DIRECTORS WITH RESPECT TO THE PERFORMANCE OF THEIR DUTIES DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“2. The discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2025”): 85,229,605 for, 1,105,840 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2025.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 24,905,221 for, 28,720 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: ADOPTION OF THE DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“1. The adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025”): 91,484,326 for, 3,855 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: The Company's shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year ended December 31, 2025”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 24,873,210 for, 28,720 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% of fund votes cast · no official result
The 55 asset managers below reported 24,879,205 for, 28,720 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 28,720 | 0 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Combines 11 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: Non-binding, advisory vote to approve the 2025 compensation of named executive officers.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“9. The 2025 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote”): 81,100,259 for, 4,946,963 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the 2025 compensation of the Company's named executive officers by a non-binding, advisory ("Say-on-Pay") vote.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,202 | 440 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 64,490 | 611,111 | 0 | 0 | Mixed |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 0 | 419,067 | 0 | 0 | Against |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 176,721 | 0 | 0 | Against |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 23,495,625 for, 1,377,375 against, 28,720 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,952,716 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 9,542,296 | 0 | 0 | 0 | For |
| FCPM III SERVICES B.V. | 9,198,900 | 0 | 0 | 0 | For |
| Fidelity | 6,414,966 | 217 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 5,673,913 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4,264,789 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 4,203,567 | 0 | 0 | 0 | For |
| Wellington | 3,701,821 | 0 | 0 | 0 | For |
| Janus Henderson | 3,481,260 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 3,445,318 | 0 | 0 | 0 | For |
| Duquesne Family Office LLC | 3,070,146 | 0 | 0 | 0 | For |
| Medicxi Ventures Management (Jersey) Ltd | 2,674,182 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,811,766 | 15,980 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 1,570,542 | 0 | 0 | Against |
| AllianceBernstein | 1,190,941 | 0 | 0 | 0 | For |
| MAVERICK CAPITAL LTD | 1,049,997 | 0 | 0 | 0 | For |
| Aberdeen | 1,004,689 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 791,021 | 0 | 0 | Against |
| Castle Hook Partners LP | 790,685 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 585,538 | 0 | 0 | 0 | For |
| TimesSquare Capital Management, LLC | 557,481 | 0 | 0 | 0 | For |
| Artia Global Partners LP | 503,936 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 481,086 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 471,557 | 0 | 0 | 0 | For |
| American Century | 0 | 450,070 | 0 | 0 | Against |
Institutional-manager reports, all 144 managers: 80,652,691 for, 4,576,341 against, 230,880 abstained, 243 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE SELECTION OF DELOITTE ACCOUNTANTS B.V. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026 BY THE AUDIT COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“4. The selection by the Company's Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026”): 91,502,639 for, 4,618 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders ratified the selection by the Company's Audit Committee of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 24,905,221 for, 28,720 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. AS THE COMPANY'S EXTERNAL AUDITOR OF THE COMPANY'S DUTCH STATUTORY ANNUAL ACCOUNTS AND DUTCH STATUTORY BOARD REPORT FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
NewAmsterdam Pharma Company N.V.’s own tally for this item (“3. The instruction to Deloitte Accounts B.V. as the external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for t”): 91,502,529 for, 4,636 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's shareholders approved the instruction to Deloitte Accounts B.V. as the external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report (including, to the extent applicable, sustainability reporting) for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 54 asset managers below reported 24,873,000 for, 28,720 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 9,331,713 | 0 | 0 | 0 | For |
| Fidelity | 5,216,459 | 0 | 0 | 0 | For |
| Vanguard | 3,200,642 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 982,142 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 957,477 | 0 | 0 | 0 | For |
| Prudential/PGIM | 675,601 | 0 | 0 | 0 | For |
| JPMorgan | 580,480 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 474,913 | 0 | 0 | 0 | For |
| American Century | 419,067 | 0 | 0 | 0 | For |
| AllianceBernstein | 404,858 | 0 | 0 | 0 | For |
| BlackRock | 340,338 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 291,102 | 0 | 0 | 0 | For |
| Federated Hermes | 238,053 | 0 | 0 | 0 | For |
| BNY Mellon | 176,721 | 0 | 0 | 0 | For |
| Victory Capital | 173,390 | 0 | 0 | 0 | For |
| Equitable | 143,848 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 132,778 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 96,492 | 0 | 0 | 0 | For |
| Principal | 87,095 | 0 | 0 | 0 | For |
| Lord Abbett | 83,119 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 81,840 | 0 | 0 | 0 | For |
| Eaton Vance | 81,652 | 0 | 0 | 0 | For |
| Allspring | 78,965 | 0 | 0 | 0 | For |
| Brighthouse | 33,524 | 0 | 28,720 | 0 | Mixed |
| OPTIMUM FUND TRUST | 60,861 | 0 | 0 | 0 | For |
Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 116,641,656 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 8.00% |
| 2 | Fidelity | 4.47% |
| 3 | Vanguard | 2.74% |
| 4 | Columbia Threadneedle | 0.84% |
| 5 | NEW ECONOMY FUND | 0.82% |
| 6 | Prudential/PGIM | 0.58% |
| 7 | JPMorgan | 0.50% |
| 8 | HARBOR FUNDS | 0.41% |
| 9 | American Century | 0.36% |
| 10 | AllianceBernstein | 0.35% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 11.10% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.18% |
| 3 | FCPM III SERVICES B.V. | 7.89% |
| 4 | Fidelity | 5.50% |
| 5 | Bain Capital Life Sciences Investors, LLC | 4.86% |
| 6 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3.66% |
| 7 | VIKING GLOBAL INVESTORS LP | 3.60% |
| 8 | Wellington | 3.17% |
| 9 | Janus Henderson | 2.98% |
| 10 | Polar Capital Holdings Plc | 2.95% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Frazier Lifesciences Sponsor LLC and affiliates | 14.75% | DEF14A |
| Capital World Investors | 10.45% | 13G |
| RA Capital Healthcare Fund, L.P. | 10.16% | DEF14A |
| Frazier Life Sciences Public Fund, L.P. | 8.94% | 13D |
| Entities affiliated with Forbion | 7.99% | DEF14A |
| FMR (Fidelity) | 7.52% | 13F |
| Entities affiliated with Bain Capital Life Sciences Investors, LLC | 6.35% | DEF14A |
| James N. Topper, M.D., Ph.D. | 6.28% | DEF14A |
| FMR LLC | 5.50% | DEF14A |
| Wellington Management | 4.39% | 13F |
Percentages above are of 116,641,656 shares outstanding, as reported by NewAmsterdam Pharma Company N.V. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NewAmsterdam Pharma Company N.V.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At NewAmsterdam Pharma Company N.V.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 185 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,577 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Non-binding, advisory vote to approve the 2025 compensation of named executive officers. — NewAmsterdam Pharma Company N.V.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NewAmsterdam Pharma Company N.V.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.
NewAmsterdam Pharma Company N.V. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.